October - 2019

MECFA Blog

Cystic fibrosis carriers at increased risk of digestive symptoms

Researchers have found that carriers of the most common genetic variant that causes cystic fibrosis experience some symptoms similar to...

First Patients Dosed in Trial Testing MS1819-SD Plus PERT for CF-related Severe EPI, AzurRX Says

AzurRx BioPharma has started dosing patients in a Phase 2 clinical trial assessing its investigational therapy MS1819-SD in combination...

New Vertex cystic fibrosis drug approved, extending treatments to 90% of patients

Vertex Pharmaceuticals on Monday won approval for its fourth treatment for cystic fibrosis, a combination drug that extends a new form of...

Prevalence and characterization of chronic rhinosinusitis in patients with non–cystic fibrosis bronc

In this retrospective cohort study, researchers identified the prevalence of chronic rhinosinusitis (CRS) among bronchiectasis patients...

CF patients experience improved lung health with lumacaftor-ivacaftor but with caveats

In adolescent and adult patients with cystic fibrosis taking lumacaftor-ivacaftor (ORKAMBI), the combination drug appears to improve lung...

Can Blood Biomarkers Predict Clinical Response to Azithromycin in Cystic Fibrosis Patients?

Although azithromycin can lower pulmonary exacerbation (PEx) risk in patients with cystic fibrosis (CF), it does not help all patients....

Viral Respiratory Tract Infections in Young CF Children Usually Mild, Study Found

Viral respiratory tract infections in young children with cystic fibrosis tend to be mild and not require hospitalization, a study found....

Evaluating the Role of New Beta-Lactam Agents for Uncommon Pathogens

Stenotrophomonas maltophilia, Achromo-bacter xylosoxidans, and Burkholderia spp are relatively uncommon pathogens that are increasingly...

Screening for cystic fibrosis-related diabetes and prediabetes: Evaluating 1,5-anhydroglucitol, fruc

Researchers examined whether alternate glycemic markers—hemoglobin A1c (HbA1c), 1,5-anhydroglucitol (1,5AG), fructosamine (FA), and...

Hexoskin Smart Shirt Can Accurately Assess Respiratory Function, May Be Tool in CF, Study Shows

Using a simple shirt — a smart one — is closer to becoming a common method to measure lung function in patients with respiratory...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p